Vascarta Outlines VAS-101's (Vasceptor®) Potential as a Non-Opioid Advance in Pain Medicine Across Sickle Cell Disease, Osteoarthritis, and Cancer

Read post on prnewswire.com

SUMMIT, N.J., Aug. 25, 2026 /PRNewswire/ -- Vascarta Inc., a clinical-stage pharmaceutical company advancing a transdermal curcuminoid therapeutic for pain and inflammation, today outlined converging preclinical and clinical evidence that its lead candidate, VAS-101 (Vasceptor®), targets...